<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879707</url>
  </required_header>
  <id_info>
    <org_study_id>49586</org_study_id>
    <nct_id>NCT03879707</nct_id>
  </id_info>
  <brief_title>Improving Sleep Quality After Total Joint Arthroplasty ( TJA)</brief_title>
  <official_title>Improving Sleep Quality After Total Joint Arthroplasty ( TJA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluate and improve sleep quality after Total joint
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in early stage after TKA tend to suffer from sleep problem. Sleep disturbances
      frequently occur in patients after surgery, and its occurrence is harmful for postoperative
      recovery. Many factors can affect the quality of sleep after a major surgery including
      anesthesia-type, narcotic use and discomfort due to pain or restricted leg movements. Pain
      directly leads to sleep disruption or even deprivation and, in turn, poor-quality sleep
      aggravates pain sensation. There seems to be a vicious circle: pain — poor-quality sleep —
      intensified pain — even poorer-quality sleep.

      Presumably, if a patient suffers from catastrophizing, depression and anxiety , the result of
      TKA will be worse due to poor sleep.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator elected not to proceed with project
  </why_stopped>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of melatonin and magnesium on pain</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of interventions on pain will be measured. It will done at follow up period of 2 wks, 6 wks and 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of melatonin on daily activities</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of interventions daily activities using VAS pain scores. Higher the score. more difficulty in performing daily activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of melatonin on daily activities</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of interventions on daily activities using Hip Disability and Osteoarthritis Outcome ( HOOS ) or Knee Disability and Osteoarthritis Outcome ( KOOS) score. The interval score ranges from 0 to 100 where 0 represents total hip/knee disability and 100 represents perfect hip/knee health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of melatonin on daily activities</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of intervention on daily activities using Western Ontario and McMaster Universities Arthritis Index (WOMAC). Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of melatonin on daily activities</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of intervention on daily activities using Pittsberg sleep quality index. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of melatonin on daily activities</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of intervention on daily activities using SF 12 score. The lower the score the more disability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain After TJA</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin and magnesium for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 5 mg</intervention_name>
    <description>Melatonin is known to induce sleep</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium 500Mg Oral Tablet</intervention_name>
    <description>Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria -Adults 18 years and older

        Exclusion criteria -

          1. No chronic pain

          2. Patients underwent revision or bilateral surgery.

          3. Patients underwent fracture.

          4. Patients suffering from dementia / delirium

          5. Patients on narcotics greater than 10mg hydrocodom before surgery

          6. Not willing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Amanatullah, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Derek Amanatullah</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

